643 related articles for article (PubMed ID: 32829028)
1. RNA-mediated toxicity in C9orf72 ALS and FTD.
McEachin ZT; Parameswaran J; Raj N; Bassell GJ; Jiang J
Neurobiol Dis; 2020 Nov; 145():105055. PubMed ID: 32829028
[TBL] [Abstract][Full Text] [Related]
2. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels.
Beckers J; Tharkeshwar AK; Van Damme P
Autophagy; 2021 Nov; 17(11):3306-3322. PubMed ID: 33632058
[TBL] [Abstract][Full Text] [Related]
3. Antisense, but not sense, repeat expanded RNAs activate PKR/eIF2α-dependent ISR in
Parameswaran J; Zhang N; Braems E; Tilahun K; Pant DC; Yin K; Asress S; Heeren K; Banerjee A; Davis E; Schwartz SL; Conn GL; Bassell GJ; Van Den Bosch L; Jiang J
Elife; 2023 Apr; 12():. PubMed ID: 37073950
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.
Jiang J; Ravits J
Neurotherapeutics; 2019 Oct; 16(4):1115-1132. PubMed ID: 31667754
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene.
Wen X; Westergard T; Pasinelli P; Trotti D
Neurosci Lett; 2017 Jan; 636():16-26. PubMed ID: 27619540
[TBL] [Abstract][Full Text] [Related]
6. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS.
Gitler AD; Tsuiji H
Brain Res; 2016 Sep; 1647():19-29. PubMed ID: 27059391
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic reduction of GGGGCC repeat RNA levels by hnRNPA3 suppresses neurodegeneration in Drosophila models of C9orf72-linked ALS/FTD.
Taminato T; Takeuchi T; Ueyama M; Mori K; Ikeda M; Mochizuki H; Nagai Y
Hum Mol Genet; 2023 May; 32(10):1673-1682. PubMed ID: 36611007
[TBL] [Abstract][Full Text] [Related]
8. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia.
Zu T; Liu Y; Bañez-Coronel M; Reid T; Pletnikova O; Lewis J; Miller TM; Harms MB; Falchook AE; Subramony SH; Ostrow LW; Rothstein JD; Troncoso JC; Ranum LP
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4968-77. PubMed ID: 24248382
[TBL] [Abstract][Full Text] [Related]
9. [Impact of C9orf72 on Japanese Patients with Amytrophic Lateral Sclerosis (ALS)/Frontotemporal Dementia (FTD)].
Tomiyama H
Brain Nerve; 2019 Nov; 71(11):1190-1208. PubMed ID: 31722305
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanisms of Neurodegeneration Related to
Babić Leko M; Župunski V; Kirincich J; Smilović D; Hortobágyi T; Hof PR; Šimić G
Behav Neurol; 2019; 2019():2909168. PubMed ID: 30774737
[TBL] [Abstract][Full Text] [Related]
11. RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3.
Ramesh N; Daley EL; Gleixner AM; Mann JR; Kour S; Mawrie D; Anderson EN; Kofler J; Donnelly CJ; Kiskinis E; Pandey UB
Acta Neuropathol Commun; 2020 Oct; 8(1):177. PubMed ID: 33129345
[TBL] [Abstract][Full Text] [Related]
12. C9ORF72 hexanucleotide repeat exerts toxicity in a stable, inducible motor neuronal cell model, which is rescued by partial depletion of Pten.
Stopford MJ; Higginbottom A; Hautbergue GM; Cooper-Knock J; Mulcahy PJ; De Vos KJ; Renton AE; Pliner H; Calvo A; Chio A; Traynor BJ; Azzouz M; Heath PR; ; Kirby J; Shaw PJ
Hum Mol Genet; 2017 Mar; 26(6):1133-1145. PubMed ID: 28158451
[TBL] [Abstract][Full Text] [Related]
13. Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia.
Stepto A; Gallo JM; Shaw CE; Hirth F
Acta Neuropathol; 2014 Mar; 127(3):377-89. PubMed ID: 24366528
[TBL] [Abstract][Full Text] [Related]
14. Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia.
Gagliardi D; Costamagna G; Taiana M; Andreoli L; Biella F; Bersani M; Bresolin N; Comi GP; Corti S
Ageing Res Rev; 2020 Dec; 64():101172. PubMed ID: 32971256
[TBL] [Abstract][Full Text] [Related]
15. SFPQ regulates the accumulation of RNA foci and dipeptide repeat proteins from the expanded repeat mutation in
Malnar M; Rogelj B
J Cell Sci; 2021 Feb; 134(4):. PubMed ID: 33495278
[TBL] [Abstract][Full Text] [Related]
16. Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD.
Niblock M; Smith BN; Lee YB; Sardone V; Topp S; Troakes C; Al-Sarraj S; Leblond CS; Dion PA; Rouleau GA; Shaw CE; Gallo JM
Acta Neuropathol Commun; 2016 Feb; 4():18. PubMed ID: 26916632
[TBL] [Abstract][Full Text] [Related]
17. How villains are made: The translation of dipeptide repeat proteins in C9ORF72-ALS/FTD.
Van't Spijker HM; Almeida S
Gene; 2023 Mar; 858():147167. PubMed ID: 36621656
[TBL] [Abstract][Full Text] [Related]
18. Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD.
Starr A; Sattler R
Brain Res; 2018 Aug; 1693(Pt A):98-108. PubMed ID: 29453960
[TBL] [Abstract][Full Text] [Related]
19. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72.
Zhu Q; Jiang J; Gendron TF; McAlonis-Downes M; Jiang L; Taylor A; Diaz Garcia S; Ghosh Dastidar S; Rodriguez MJ; King P; Zhang Y; La Spada AR; Xu H; Petrucelli L; Ravits J; Da Cruz S; Lagier-Tourenne C; Cleveland DW
Nat Neurosci; 2020 May; 23(5):615-624. PubMed ID: 32284607
[TBL] [Abstract][Full Text] [Related]
20. All in the Family: Repeats and ALS/FTD.
Pattamatta A; Cleary JD; Ranum LPW
Trends Neurosci; 2018 May; 41(5):247-250. PubMed ID: 29703376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
